SecBot SecBot
Insider Cluster (2 insiders) ·Filed Mar 5, 2026

DYN

Dyne Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed8mo ago
Insider cluster: 2 insiders, $54K total
Actionable Insight • Neutral

Monitor for additional selling in the next 30 days; isolated small sales by executives are common and typically not predictive, but pattern changes could signal shifting sentiment.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$15.20
T+0 close · Mar 4, 2026 · via day close
Latest settled
+22.57%
T+60 · $18.63
Vs SPY
+11.27%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 5 $15.20entry
  2. T+1 · 9mo ago −2.24%α −0.92% · $14.86
  3. T+5 · 8mo ago +18.82%α +21.05% · $18.06
  4. T+20 · 8mo ago +23.95%α +27.74% · $18.84
  5. T+60 · 6mo ago +22.57%α +11.27% · $18.63
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two top executives at Dyne Therapeutics, the CEO and Chief Medical Officer, sold shares in a coordinated open-market transaction totaling approximately $54,200. The sales represent a routine divestiture with minimal dollar value relative to the company's $2.5B market cap.

Key Financial Metrics

Direction
selling
Total Value
$54.2K
Insiders
2

Key Facts

  • CEO John Cox sold 2,732 shares for $40,706.80 in an open-market transaction.
  • Chief Medical Officer Douglas Kerr sold 904 shares for $13,469.60, also via open-market sale.
  • Total value of insider sales: $54,176.40 across two C-suite executives.
  • Sales occurred on the same day at $14.90 per share, within normal trading activity.
  • Total value represents only 0.002% of Dyne Therapeutics' $2.5B market capitalization.

Financial Impact

$54,176 in total open-market sales by C-suite executives

insider ownershipmarket sentiment

Risk Factors

  • Perception of insider confidence may be slightly weakened, though the dollar amount is negligible.
  • Concurrent sales by CEO and CMO could raise questions if followed by negative news or lack of progress in clinical programs.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CONTEXT: Insider Cluster Data (2 trades, 7d window)cluster-DYN-1772831364149

Track record

54 reports on DYN

Performance horizon

12 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 15 of 16 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
  2. Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
  3. Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
  4. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  5. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
  6. Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
  7. Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
  8. Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
  9. Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
  10. Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
Showing 10 of 54

US Market Status

Market Closed · Opens Wed (11h 36m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 6, 2026